AbatacepT foR ImmUne checkpoint inhibitor associated myocarditis (ATRIUM): a phase 3, investigator-initiated, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Abatacept compared to Placebo in hospitalized participants with immune checkpoint inhibitor associated myocarditis

Description

The primary aim is to test whether abatacept, as compared to placebo, is associated with a reduction in major adverse cardiac events (MACE) among participants hospitalized with myocarditis secondary to an immune checkpoint inhibitor (ICI). The primary outcome, MACE, is a composite of first occurrence of cardiovascular death, non-fatal sudden cardiac arrest, cardiogenic shock, significant ventricular arrythmias, significant bradyarrythmias, or incident heart failure.

Resources and Links

Phone Number: 1-877-MDA-6789

clinicaltrials.gov NCT No: NCT05335928 Opens a new window